Dutch chemicals group Akzo Nobel has posted net income of 455 millionguilders ($230.3 million) for the third quarter ended September, 1997, up 38.7% on the same period a year ago. Overall group sales reached 6.1 billion guilders, an increase of 11%, which was caused by volume gains and currency movements.
Pharmaceuticals, which contributed around 19.5% of total revenues, produced sales of 1.18 guilders, an increase of 23%, with operating income rising almost 30%. The boost in operating income was due to the strong performance of the group's subsidiary, Organon, which posted volume gains for oral contraceptives and the antidepressant Remeron (mirtazapine). All its other sectors, most notably chemicals, performed strongly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze